LONDON – NICE Guidance on Hormone Replacement Therapy (HRT)
In a recent update, the UK’s health assessment body NICE has determined that Hormone Replacement Therapy (HRT) does not impact the life expectancy of individuals using it to alleviate menopause symptoms.
Comprehensive Analysis
The conclusion follows a thorough examination of data regarding the correlation between HRT and various conditions like heart disease, stroke, certain cancers, and dementia.
New Guidance and Discussion Aid
NICE has introduced a discussion aid to assist GPs in providing patients with essential information about the drugs and their functions. The guidance also suggests the inclusion of talking therapy alongside HRT to help women manage symptoms.
HRT Administration and Guidelines
HRT involves the replacement of estrogen or progestogen, or both, when menstruation ceases, typically between ages 45 and 55. It can be administered through gels, creams, pessaries, tablets, or sprays.
Personalized Treatment Approach
Healthcare professionals are advised to consider each woman’s individual circumstances and provide necessary information to facilitate informed treatment decisions. While there are increased risks associated with HRT, it is unlikely to impact overall life expectancy.
Risk Assessment and Benefits
The guidance emphasizes that the risk of developing certain health conditions with HRT is illustrated clearly to aid GPs in discussions with patients. Available scientific evidence was evaluated by an independent panel to compile this information.
Beneficial Effects of HRT
HRT has shown to reduce the risk of fractures related to osteoporosis, a condition more prevalent post-menopause. However, there is a slight increase in the risk of breast cancer with long-term HRT use.
Supportive Measures
NICE recommends HRT as the primary treatment for menopause symptoms like hot flushes and night sweats. Additionally, cognitive behavioral therapy (CBT) is to be offered alongside or in place of HRT for women over 40.
Increasing Awareness and Support
Prescriptions for HRT have risen in the UK, reflecting a growing understanding of menopause symptoms’ impact on women. However, efforts are needed to better support women from ethnic minority backgrounds and disadvantaged areas.
“Women need to feel confident in receiving tailored advice and support to make informed choices that suit their needs,” stated Professor Jonathan Benger, Chief Medical Officer at NICE.
